In conclusion, these data indicate differing roles for CCR2-CCL2 and FGF21 pathways in the pathogenesis of liver fibrosis and chronic steatohepatitis in human NAFLD, corroborating the potential distinct benefits of pharmacological targeting each pathway. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatotic liver disease.